ABILIFY TABLET Canada - English - Health Canada

abilify tablet

otsuka pharmaceutical co ltd - aripiprazole - tablet - 10mg - aripiprazole 10mg - atypical antipsychotics

ABILIFY TABLET Canada - English - Health Canada

abilify tablet

otsuka pharmaceutical co ltd - aripiprazole - tablet - 15mg - aripiprazole 15mg - atypical antipsychotics

ABILIFY TABLET Canada - English - Health Canada

abilify tablet

otsuka pharmaceutical co ltd - aripiprazole - tablet - 30mg - aripiprazole 30mg - atypical antipsychotics

ABILIFY MAINTENA- aripiprazole kit United States - English - NLM (National Library of Medicine)

abilify maintena- aripiprazole kit

otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 300 mg in 1.5 ml - abilify maintena (aripiprazole) is indicated for: - treatment of schizophrenia in adults [see clinical studies (14.1)] - maintenance monotherapy treatment of bipolar i disorder in adults [see clinical studies (14.2)] abilify maintena is contraindicated in patients with a known hypersensitivity to aripiprazole. hypersensitivity reactions ranging from pruritus/urticaria to anaphylaxis have been reported in patients receiving aripiprazole [see adverse reactions (6.1 and 6.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abilify during pregnancy. for more information contact the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/. risk summary neonates exposed to antipsychotic drugs, including abilify maintena, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms. there are insufficient data with abilify maintena use in pregnant women to inform a drug-associated risk. in animal reproduction studies, oral and intravenous aripiprazole administration during organogenesis in rats and/or rabbits at doses 10 and 11 times, respectively, the maximum recommended human dose (mrhd) produced fetal death, decreased fetal weight, undescended testicles, delayed skeletal ossification, skeletal abnormalities, and diaphragmatic hernia. oral and intravenous aripiprazole administration during the pre- and post-natal period in rats at doses 10 times the mrhd produced prolonged gestation, stillbirths, decreased pup weight, and decreased pup survival. consider the benefits and risks of abilify maintena and possible risks to the fetus when prescribing abilify maintena to a pregnant woman. advise pregnant women of potential fetal risk. the background risk of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations fetal/neonatal adverse reactions extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs (including oral aripiprazole) during the third trimester of pregnancy. these symptoms have varied in severity. some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization. monitor neonates exhibiting extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately. animal data in animal studies, aripiprazole demonstrated developmental toxicity, including possible teratogenic effects in rats and rabbits. pregnant rats were treated with oral doses of 3, 10, and 30 mg/kg/day which are approximately 1 to 10 times the mrhd of 30 mg/day on mg/m2 basis of aripiprazole during the period of organogenesis. treatment at the highest dose caused a slight prolongation of gestation and delay in fetal development, as evidenced by decreased fetal weight and undescended testes. delayed skeletal ossification was observed at 3 and 10 times the oral mrhd on mg/m2 basis. at 3 and 10 times the oral mrhd on mg/m2 basis, delivered offspring had decreased body weights. increased incidences of hepatodiaphragmatic nodules and diaphragmatic hernia were observed in offspring from the highest dose group (the other dose groups were not examined for these findings). postnatally, delayed vaginal opening was seen at 3 and 10 times the oral mrhd on mg/m2 basis and impaired reproductive performance (decreased fertility rate, corpora lutea, implants, live fetuses, and increased post-implantation loss, likely mediated through effects on female offspring) along with some maternal toxicity were seen at the highest dose; however, there was no evidence to suggest that these developmental effects were secondary to maternal toxicity. in pregnant rats treated with aripiprazole intravenously at doses of 3, 9, and 27 mg/kg/day, which are 1 to 9 times the oral mrhd on mg/m2 basis, during the period of organogenesis, decreased fetal weight and delayed skeletal ossification were seen at the highest dose which also caused maternal toxicity. in pregnant rabbits treated with oral doses of 10, 30, and 100 mg/kg/day which are 2 to 11 times human exposure at the oral mrhd based on auc and 6 to 65 times the oral mrhd of aripiprazole on mg/m2 basis during the period of organogenesis, decreased maternal food consumption and increased abortions were seen at the highest dose as well as increased fetal mortality. decreased fetal weight and increased incidence of fused sternebrae were observed at 3 and 11 times the mrhd based on auc. in pregnant rabbits receiving aripiprazole injection intravenously at doses of 3, 10, and 30 mg/kg/day, which are 2 to 19 times the oral mrhd on mg/m2 basis during the period of organogenesis, the highest dose caused pronounced maternal toxicity that resulted in decreased fetal weight, increased fetal abnormalities (primarily skeletal), and decreased fetal skeletal ossification. the fetal no-effect dose was 5 times the human exposure at the oral mrhd based on auc and is 6 times the oral mrhd on mg/m2 basis. in rats treated with oral doses of 3, 10, and 30 mg/kg/day, which are 1 to 10 times the oral mrhd of aripiprazole on a mg/m2 basis, peri- and post-natally (from day 17 of gestation through day 21 postpartum), slight maternal toxicity and slightly prolonged gestation were seen at the highest dose. an increase in stillbirths and decreases in pup weight (persisting into adulthood) and survival were also seen at this dose. in rats treated with aripiprazole intravenously at doses of 3, 8, and 20 mg/kg/day which are 1 to 6 times the oral mrhd on mg/m2 basis from day 6 of gestation through day 20 postpartum, increased stillbirths were seen at 3 and 6 times the mrhd on mg/m2 basis, and decreases in early postnatal pup weight and survival were seen at the highest dose; these doses produced some maternal toxicity. there were no effects on postnatal behavioral and reproductive development. risk summary aripiprazole is present in human breast milk; however, there are insufficient data to assess the amount in human milk, the effects on the breastfed infant, or the effects on milk production. the development and health benefits of breastfeeding should be considered along with the mother's clinical need for abilify maintena and any potential adverse effects on the breastfed infant from abilify maintena or from the underlying maternal condition. abilify maintena has not been studied in children 18 years of age or younger. however, juvenile animal studies have been conducted in rats and dogs. juvenile animal studies aripiprazole in juvenile rats caused mortality, cns clinical signs, impaired memory and learning, and delayed sexual maturation when administered at oral doses of 10, 20, 40 mg/kg/day from weaning (21 days old) through maturity (80 days old). at 40 mg/kg/day, mortality, decreased activity, splayed hind limbs, hunched posture, ataxia, tremors and other cns signs were observed in both genders. in addition, delayed sexual maturation was observed in males. at all doses and in a dose-dependent manner, impaired memory and learning, increased motor activity, and histopathology changes in the pituitary (atrophy), adrenals (adrenocortical hypertrophy), mammary glands (hyperplasia and increased secretion), and female reproductive organs (vaginal mucification, endometrial atrophy, decrease in ovarian corpora lutea) were observed. the changes in female reproductive organs were considered secondary to the increase in prolactin serum levels. a no observed adverse effect level (noael) could not be determined and, at the lowest tested dose of 10 mg/kg/day, there is no safety margin relative to the systemic exposures (auc0-24 ) for aripiprazole or its major active metabolite in adolescents at the maximum recommended pediatric dose of 15 mg/day. all drug-related effects were reversible after a 2-month recovery period, and most of the drug effects in juvenile rats were also observed in adult rats from previously conducted studies. aripiprazole in juvenile dogs (2 months old) caused cns clinical signs of tremors, hypoactivity, ataxia, recumbency and limited use of hind limbs when administered orally for 6 months at 3, 10, 30 mg/kg/day. mean body weight and weight gain were decreased up to 18% in females in all drug groups relative to control values. a noael could not be determined and, at the lowest tested dose of 3 mg/kg/day, there is no safety margin relative to the systemic exposures (auc0-24 ) for aripiprazole or its major active metabolite in adolescents at the maximum recommended pediatric dose of 15 mg/day. all drug-related effects were reversible after a 2-month recovery period. clinical studies of oral aripiprazole did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. other reported clinical experience and pharmacokinetic data [see clinical pharmacology (12.3)] have not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. in single-dose and multiple-dose pharmacokinetic studies, there was no detectable age effect in the population pharmacokinetic analysis of oral aripiprazole in schizophrenia patients [see clinical pharmacology (12.3)] . no dosage adjustments are recommended based on age alone. abilify maintena is not approved for the treatment of patients with dementia-related psychosis [see also boxed warning and warnings and precautions (5.1)]. dosage adjustment is recommended in known cyp2d6 poor metabolizers due to high aripiprazole concentrations. approximately 8% of caucasians and 3% to 8% of black/african americans cannot metabolize cyp2d6 substrates and are classified as poor metabolizers (pm) [see dosage and administration (2.3) and clinical pharmacology (12.3)] . no dosage adjustment for abilify maintena is required on the basis of a patient's hepatic function (mild to severe hepatic impairment, child-pugh score between 5 and 15), or renal function (mild to severe renal impairment, glomerular filtration rate between 15 and 90 ml/minute) [see clinical pharmacology (12.3)] . no dosage adjustment for abilify maintena is required on the basis of a patient's sex, race, or smoking status [see clinical pharmacology (12.3)] .

ABILIFY MYCITE- aripiprazole tablet with sensor United States - English - NLM (National Library of Medicine)

abilify mycite- aripiprazole tablet with sensor

otsuka america pharmaceutical, inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - abilify mycite, a drug-device combination product comprised of aripiprazole tablets embedded with an ingestible event marker (iem) sensor intended to track drug ingestion, is indicated for the: - treatment of adults with schizophrenia. - treatment of bipolar i disorder acute treatment of adults with manic and mixed episodes as monotherapy and as adjunct to lithium or valproate. maintenance treatment of adults as monotherapy and as adjunct to lithium or valproate. - acute treatment of adults with manic and mixed episodes as monotherapy and as adjunct to lithium or valproate. - maintenance treatment of adults as monotherapy and as adjunct to lithium or valproate. - adjunctive treatment of adults with major depressive disorder. limitations of use: - the ability of the abilify mycite to improve patient compliance or modify aripiprazole dosage has not been established [see dosage and administration (2.1)] . - the use of abilify mycite to track drug ingestion in "real-time" or during an emergency is not recommended

ABILIFY ASIMTUFII- aripiprazole injection, suspension, extended release United States - English - NLM (National Library of Medicine)

abilify asimtufii- aripiprazole injection, suspension, extended release

otsuka america pharmaceutical, inc - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - abilify asimtufii is indicated: - for the treatment of schizophrenia in adults - for maintenance monotherapy treatment of bipolar i disorder in adults abilify asimtufii is contraindicated in patients with a known hypersensitivity to aripiprazole, or any of the excipients. hypersensitivity reactions ranging from pruritus/urticaria to anaphylaxis have been reported in patients receiving aripiprazole [see adverse reactions (6.1)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/ . risk summary neonates exposed to antipsychotic drugs, including abilify asimtufii, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms (see clinical considerations) . there are insufficient data with abilify asimtufii use in pregnant women to inform a drug-associated risk. in animal reproduction studies, oral and intravenous aripiprazole administration during organogenesis in rats and/or rabbits at doses 10 and 11 times, respectively, the maximum recommended human oral dose (mrhd) produced fetal death, decreased fetal weight, undescended testicles, delayed skeletal ossification, skeletal abnormalities, and diaphragmatic hernia. oral and intravenous aripiprazole administration during the pre- and post-natal period in rats at doses 10 times the oral mrhd produced prolonged gestation, stillbirths, decreased pup weight, and decreased pup survival (see data) . consider the benefits and risks of abilify asimtufii and possible risks to the fetus when prescribing abilify asimtufii to a pregnant woman. advise pregnant women of potential fetal risk. the background risk of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations fetal/neonatal adverse reactions extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs, including oral aripiprazole, during the third trimester of pregnancy. these symptoms have varied in severity. some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization. monitor neonates exhibiting extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately. data animal data no developmental toxicity studies were conducted with intramuscular aripiprazole suspension. in animal oral or intravenous studies, aripiprazole demonstrated developmental toxicity, including possible teratogenic effects in rats and rabbits. pregnant rats were treated with oral doses of 3, 10, and 30 mg/kg/day which are approximately 1 to 10 times the oral mrhd of 30 mg/day on mg/m2 basis of aripiprazole during the period of organogenesis. treatment at the highest dose caused a slight prolongation of gestation and delay in fetal development, as evidenced by decreased fetal weight and undescended testes. delayed skeletal ossification was observed at 3 and 10 times the oral mrhd on mg/m2 basis. at 3 and 10 times the oral mrhd on mg/m2 basis, delivered offspring had decreased body weights. increased incidences of hepatodiaphragmatic nodules and diaphragmatic hernia were observed in offspring from the highest dose group (the other dose groups were not examined for these findings). postnatally, delayed vaginal opening was seen at 3 and 10 times the oral mrhd on mg/m2 basis and impaired reproductive performance (decreased fertility rate, corpora lutea, implants, live fetuses, and increased post-implantation loss, likely mediated through effects on female offspring) along with some maternal toxicity were seen at the highest dose; however, there was no evidence to suggest that these developmental effects were secondary to maternal toxicity. in pregnant rats treated with aripiprazole intravenously at doses of 3, 9, and 27 mg/kg/day, which are 1 to 9 times the oral mrhd on mg/m2 basis, during the period of organogenesis, decreased fetal weight and delayed skeletal ossification were seen at the highest dose which also caused maternal toxicity. in pregnant rabbits treated with oral doses of 10, 30, and 100 mg/kg/day which are 2 to 11 times human exposure at the oral mrhd based on auc and 6 to 65 times the oral mrhd of aripiprazole on mg/m2 basis during the period of organogenesis, decreased maternal food consumption and increased abortions were seen at the highest dose as well as increased fetal mortality. decreased fetal weight and increased incidence of fused sternebrae were observed at 3 and 11 times the oral mrhd based on auc. in pregnant rabbits receiving aripiprazole injection intravenously at doses of 3, 10, and 30 mg/kg/day, which are 2 to 19 times the oral mrhd on mg/m2 basis during the period of organogenesis, the highest dose caused pronounced maternal toxicity that resulted in decreased fetal weight, increased fetal abnormalities (primarily skeletal), and decreased fetal skeletal ossification. the fetal no-effect dose was 5 times the human exposure at the oral mrhd based on auc and is 6 times the oral mrhd on mg/m2 basis. in rats treated with oral doses of 3, 10, and 30 mg/kg/day, which are 1 to 10 times the oral mrhd of aripiprazole on a mg/m2 basis, peri- and post-natally (from day 17 of gestation through day 21 postpartum), slight maternal toxicity and slightly prolonged gestation were seen at the highest dose. an increase in stillbirths and decreases in pup weight (persisting into adulthood) and survival were also seen at this dose. in rats treated with aripiprazole intravenously at doses of 3, 8, and 20 mg/kg/day which are 1 to 6 times the oral mrhd on mg/m2 basis from day 6 of gestation through day 20 postpartum, increased stillbirths were seen at 3 and 6 times the oral mrhd on mg/m2 basis, and decreases in early postnatal pup weight and survival were seen at the highest dose; these doses produced some maternal toxicity. there were no effects on postnatal behavioral and reproductive development. risk summary aripiprazole is present in human breast milk; however, there are insufficient data to assess the amount in human milk, the effects on the breastfed infant, or the effects on milk production. the development and health benefits of breastfeeding should be considered along with the mother's clinical need for abilify asimtufii and any potential adverse effects on the breastfed infant from abilify asimtufii or from the underlying maternal condition. safety and effectiveness of abilify asimtufii in pediatric patients have not been established. juvenile animal studies no juvenile animal studies were conducted with intramuscular aripiprazole suspension. a study with oral aripiprazole in juvenile rats caused mortality, cns clinical signs, impaired memory and learning, and delayed sexual maturation when administered at doses of 10, 20, 40 mg/kg/day from weaning (21 days old) through maturity (80 days old). at 40 mg/kg/day, mortality, decreased activity, splayed hind limbs, hunched posture, ataxia, tremors and other cns signs were observed in both genders. in addition, delayed sexual maturation was observed in males. at all doses and in a dose-dependent manner, impaired memory and learning, increased motor activity, and histopathology changes in the pituitary (atrophy), adrenals (adrenocortical hypertrophy), mammary glands (hyperplasia and increased secretion), and female reproductive organs (vaginal mucification, endometrial atrophy, decrease in ovarian corpora lutea) were observed. the changes in female reproductive organs were considered secondary to the increase in prolactin serum levels. a no observed adverse effect level (noael) could not be determined and, at the lowest tested dose of 10 mg/kg/day, there is no safety margin relative to the systemic exposures (auc0-24 ) for aripiprazole or its major active metabolite in adolescents at the maximum recommended oral pediatric dose of 15 mg/day. all drug-related effects were reversible after a 2-month recovery period, and most of the drug effects in juvenile rats were also observed in adult rats from previously conducted studies. aripiprazole in juvenile dogs (2 months old) caused cns clinical signs of tremors, hypoactivity, ataxia, recumbency and limited use of hind limbs when administered orally for 6 months at 3, 10, 30 mg/kg/day. mean body weight and weight gain were decreased up to 18% in females in all drug groups relative to control values. a noael could not be determined and, at the lowest tested dose of 3 mg/kg/day, there is no safety margin relative to the systemic exposures (auc0-24 ) for aripiprazole or its major active metabolite in adolescents at the maximum recommended oral pediatric dose of 15 mg/day. all drug-related effects were reversible after a 2-month recovery period. clinical studies of abilify asimtufii did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. other reported clinical experience and pharmacokinetic data have not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. in single-dose and multiple-dose pharmacokinetic studies with oral aripiprazole, there was no detectable age effect in the population pharmacokinetic analysis in schizophrenia patients. no dosage adjustments are recommended based on age alone. abilify asimtufii is not approved for the treatment of patients with dementia-related psychosis [see also boxed warning and warnings and precautions (5.1)]. dosage adjustment is recommended in known cyp2d6 poor metabolizers due to high aripiprazole concentrations. approximately 8% of caucasians and 3% to 8% of black/african americans cannot metabolize cyp2d6 substrates and are classified as poor metabolizers (pm) [see dosage and administration (2.4)] . no dosage adjustment for abilify asimtufii is required on the basis of a patient's renal function (mild to severe renal impairment, glomerular filtration rate between 15 and 90 ml/minute) [see dosage and administration (2.4)] . no dosage adjustment for abilify asimtufii is required on the basis of a patient's hepatic function (mild to severe hepatic impairment, child-pugh score between 5 and 15). abilify asimtufii (a-bil-i-fy ah-sim-tuh-fye) (aripiprazole) extended-release injectable suspension the following information is intended for medical or healthcare professionals only and should be read by the medical or healthcare professional in conjunction with the full prescribing information. - read the complete instructions for preparation and administration below before administering abilify asimtufii. - to be prepared and administered only by a healthcare professional once every two months. - abilify asimtufii pre-filled syringe is single-dose only . re-use may lead to infection or other illness/injury. - for gluteal intramuscular injection only. do not administer by any other route. - prior to administration, visually inspect abilify asimtufii pre-filled syringe for particulate matter and discoloration. the suspension should appear to be a uniform, homogeneous suspension that is opaque and milky-white in color. do not use abilify asimtufii pre-filled syringe if the suspension is discolored, or particulate matter is present. contents of kit each kit contains one sterile pre-filled syringe containing abilify asimtufii (aripiprazole) 720 mg or 960 mg extended-release injectable suspension and two safety needles: - one sterile 1 ½ inch 22 gauge needle (in black packaging) - one sterile 2 inch 21 gauge needle (in green packaging) preparation prior to administration - remove the abilify asimtufii pre-filled syringe from the package. - tap the syringe on your hand at least 10 (ten) times (figure 1). - after tapping, shake the syringe vigorously for at least 10 (ten) seconds until the medication is uniform (figure 2). figure 1

figure 2

figure 1 figure 2 select the appropriate needle needle selection is determined by patient body type. for gluteal intramuscular administration only. - for non-obese patients - 22-gauge, 1.5-inch (38 mm) safety needle with needle protection device (needle in black packaging) - for obese patients - 21-gauge, 2-inch (51 mm) safety needle with needle protection device (needle in green packaging) refer to table 1 below for needle information: attach the needle - twist and pull off the pre-filled syringe tip-cap (figure 3). - while holding the base of the needle, ensure the needle is firmly seated on the safety device with a push. gently twist clockwise until securely fitted (figure 3). figure 3 expel air - when you are ready to administer the injection of abilify asimtufii, hold the pre-filled syringe upright and remove the needle-cap straight up (figure 4). do not twist the needle-cap, as this may loosen the needle from the syringe. figure 4 - slowly advance the plunger rod upward to expel the air and until the suspension fills needle base (figure 5). figure 5 inject the dose - slowly inject the entire contents of the pre-filled syringe intramuscularly into the gluteal muscle of the patient (figure 6). do not administer by any other route. do not massage the injection site. figure 6 disposal procedure - after the injection, press the safety shield on a hard surface to cover and lock shield over the needle (figure 7 and 8) figure 7 figure 8 - immediately discard used syringe and the unused needle in an approved sharps container (figure 9). - the unused needle should not be saved for future use. figure 9

ABILIFY ORAL SOLUTION 1MGML Singapore - English - HSA (Health Sciences Authority)

abilify oral solution 1mgml

otsuka pharmaceuticals (singapore) pte. ltd. - aripiprazole - solution - aripiprazole 1.0 mg/ml

ABILIFY TABLET 2MG Singapore - English - HSA (Health Sciences Authority)

abilify tablet 2mg

otsuka pharmaceuticals (singapore) pte. ltd. - aripiprazole - tablet - aripiprazole 2mg

Abilify Maintena New Zealand - English - Medsafe (Medicines Safety Authority)

abilify maintena

pharmacy retailing (nz) ltd t/a healthcare logistics - aripiprazole monohydrate 312.05mg equivalent to aripiprazole 300 mg;   - injection with diluent - 300 mg - excipient: water for injection active: aripiprazole monohydrate 312.05mg equivalent to aripiprazole 300 mg   excipient: carmellose sodium mannitol monobasic sodium phosphate monohydrate sodium hydroxide - for maintenance of clinical improvement in the treatment of schizophrenia

Abilify Maintena New Zealand - English - Medsafe (Medicines Safety Authority)

abilify maintena

pharmacy retailing (nz) ltd t/a healthcare logistics - aripiprazole monohydrate 416.07mg equivalent to aripiprazole 400 mg;   - injection with diluent - 400 mg - active: aripiprazole monohydrate 416.07mg equivalent to aripiprazole 400 mg   excipient: carmellose sodium mannitol monobasic sodium phosphate monohydrate sodium hydroxide water for injection - for maintenance of clinical improvement in the treatment of schizophrenia